Asset Medikal
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Asset Medikal - overview
Established
2009
Location
Istanbul, kucukcekmece, Turkey
Primary Industry
Medical Devices & Equipment
About
Asset Medikal is a Turkish company specializing in the design and manufacturing of advanced infusion therapy solutions, focusing on innovative needle-free technology for healthcare providers worldwide. Founded in 2009 in Istanbul, Turkey, Asset Medikal focuses on creating cutting-edge infusion therapy products. The firm underwent a significant change in ownership in 2016 when Pera Capital Partners acquired a controlling stake. The company is led by CEO Saul Umbrasas, while Füsun Tüysüz is noted as a founder with potential prior entrepreneurial experience.
Asset Medical specializes in advanced infusion therapy solutions, particularly needle-free technology. Their core products include FlowArt® One Directional Needle-Free Valves to prevent reflux-related occlusions, NeutrArt® Neutral Displacement Needle-Free Connectors for safe fluid administration, and SwabArt® Disinfecting Caps designed to protect patients from infections. These offerings cater to various healthcare sectors like anesthesia, dialysis, and intensive care, reaching markets in North America, Europe, Asia, and Latin America, adhering to international standards enforced by organizations such as the FDA and CE. Asset Medical generates revenue through direct sales of its infusion therapy products and OEM contracts with global medical device manufacturers for private labeling.
The company’s B2B partnerships involve hospitals and healthcare facilities purchasing essential components like needle-free valves and connectors, predominantly through bulk orders that may include negotiated pricing based on volume for key products such as FlowArt® and NeutrArt®. Going forward, Asset Medikal plans to launch new products to enhance its infusion therapy range, with specific release dates to be announced. The company aims to expand into additional markets, particularly in Asia and Europe by 2025. The financing from the acquisition in 2016 will support these initiatives, enabling the firm to advance its product development and market expansion strategies.
Current Investors
Pera Capital Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Devices & Equipment
Website
http://www.assetmedikal.com/
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Asset Medikal - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Asset Medikal | - |
Displaying 1 - 1 of 1
Asset Medikal - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.